Evaluation of Intra-Articular Amikacin Administration in an Equine Non-inflammatory Joint Model to Identify Effective Bactericidal Concentrations While Minimizing Cytotoxicity.
Authors: Pezzanite Lynn, Chow Lyndah, Hendrickson Dean, Gustafson Daniel L, Russell Moore A, Stoneback Jason, Griffenhagen Gregg M, Piquini Gabriella, Phillips Jennifer, Lunghofer Paul, Dow Steven, Goodrich Laurie R
Journal: Frontiers in veterinary science
Summary
# Editorial Summary Septic arthritis remains a serious clinical challenge in equine medicine, particularly where multidrug-resistant pathogens are involved, yet guidance on safe and effective intra-articular antibiotic dosing has been limited. Researchers used an equine joint model to evaluate three amikacin doses (500, 125, and 31.25 mg) injected directly into the tibiotarsal joint, measuring synovial fluid antibiotic concentrations, inflammatory markers, and cartilage degradation products over 24 hours, alongside in vitro cytotoxicity studies on equine joint cells. All three doses achieved concentrations exceeding the minimum inhibitory concentration for common equine joint pathogens throughout the 24-hour period; however, the highest dose (500 mg) triggered significant elevations in TNF-α and IL-1β, with increased markers of type II collagen degradation (C2C and C12C), suggesting direct cartilage damage. The mechanism appears to involve antibiotic-induced apoptosis of synovial cells with subsequent phagocytosis by macrophages, whilst neutrophils and T cells were particularly susceptible to aminoglycoside cytotoxicity at clinical concentrations—potentially explaining the paradoxical absence of elevated synovial cell counts despite an inflammatory cytokine response. These findings suggest that lower intra-articular amikacin doses than those conventionally reported in equine practice may achieve bactericidal efficacy whilst substantially reducing iatrogenic joint inflammation and chondrotoxicity, prompting reconsideration of dosing protocols in clinical septic arthritis cases.
Read the full abstract on PubMed
Practical Takeaways
- •If using intra-articular amikacin for septic arthritis, consider doses lower than traditionally recommended (start at 125 mg or less) to maintain pathogen kill while reducing damage to joint cartilage and immune function
- •High-dose intra-articular aminoglycosides may paradoxically impair local immune response by killing protective neutrophils and T cells—balance antimicrobial efficacy against immunosuppression
- •Monitor closely for cartilage degradation and systemic infection when using intra-articular aminoglycosides, as cytotoxicity to synovial cells may mask clinical signs of inflammation
Key Findings
- •All three amikacin doses (500, 125, 31.25 mg) maintained synovial fluid concentrations above the MIC for common equine joint pathogens for 24 hours
- •The highest amikacin dose (500 mg) significantly increased inflammatory cytokines TNF-α and IL-1β and cartilage degradation markers (C2C, C12C) despite no increase in total cell counts
- •Aminoglycosides kill chondrocytes, synoviocytes, neutrophils, and T cells at clinically relevant doses through apoptosis, potentially blunting protective immune responses
- •Lower intra-articular amikacin doses may achieve bactericidal efficacy while reducing cytotoxicity to joint tissues and immune cells